| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lea J Mertens, Matthew B Wall, Leor Roseman, Lysia Demetriou, David J Nutt, Robin L Carhart-Harri. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England). vol 34. issue 2. 2021-01-11. PMID:31941394. |
therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. |
2021-01-11 |
2023-08-13 |
Not clear |
| Lea J Mertens, Matthew B Wall, Leor Roseman, Lysia Demetriou, David J Nutt, Robin L Carhart-Harri. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England). vol 34. issue 2. 2021-01-11. PMID:31941394. |
psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. |
2021-01-11 |
2023-08-13 |
Not clear |
| Ana Sofia Vargas, Ângelo Luís, Mário Barroso, Eugenia Gallardo, Luísa Pereir. Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials. Biomedicines. vol 8. issue 9. 2020-10-20. PMID:32899469. |
psilocybin as a new approach to treat depression and anxiety in the context of life-threatening diseases-a systematic review and meta-analysis of clinical trials. |
2020-10-20 |
2023-08-13 |
Not clear |
| Ana Sofia Vargas, Ângelo Luís, Mário Barroso, Eugenia Gallardo, Luísa Pereir. Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials. Biomedicines. vol 8. issue 9. 2020-10-20. PMID:32899469. |
recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. |
2020-10-20 |
2023-08-13 |
Not clear |
| David Nutt, David Erritzoe, Robin Carhart-Harri. Psychedelic Psychiatry's Brave New World. Cell. vol 181. issue 1. 2020-10-16. PMID:32243793. |
outcomes of neuroscience and clinical research into 5-hydroxytryptamine 2a (5-ht2a) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction. |
2020-10-16 |
2023-08-13 |
Not clear |
| Ananya Mahapatra, Rishi Gupt. Role of psilocybin in the treatment of depression. Therapeutic advances in psychopharmacology. vol 7. issue 1. 2020-10-01. PMID:28101325. |
role of psilocybin in the treatment of depression. |
2020-10-01 |
2023-08-13 |
Not clear |
| Tara C Malone, Sarah E Mennenga, Jeffrey Guss, Samantha K Podrebarac, Lindsey T Owens, Anthony P Bossis, Alexander B Belser, Gabrielle Agin-Liebes, Michael P Bogenschutz, Stephen Ros. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:29666578. |
a double-blind controlled trial was performed, where 29 patients with cancer-related anxiety and depression were randomly assigned to treatment with single-dose psilocybin (0.3 mg/kg) or niacin in conjunction with psychotherapy. |
2020-10-01 |
2023-08-13 |
human |
| Taylor Lyons, Robin Lester Carhart-Harri. More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. Frontiers in psychology. vol 9. 2020-10-01. PMID:30369890. |
more realistic forecasting of future life events after psilocybin for treatment-resistant depression. |
2020-10-01 |
2023-08-13 |
Not clear |
| Leor Roseman, David J Nutt, Robin L Carhart-Harri. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in pharmacology. vol 8. 2020-09-29. PMID:29387009. |
quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. |
2020-09-29 |
2023-08-13 |
Not clear |
| Kristin Heuschkel, Kim P C Kuyper. Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32296353. |
depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. |
2020-09-28 |
2023-08-13 |
Not clear |
| Kristin Heuschkel, Kim P C Kuyper. Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32296353. |
to that end, the individual effects of mm and psilocybin, and their underlying working mechanisms, were compared on a non-exhaustive selection of six prominent psychological and biological processes that are well known to show impairments in patients suffering from major depression disorder, that is mood, executive functioning, social skills, neuroplasticity, core neural networks, and neuroendocrine and neuroimmunological levels. |
2020-09-28 |
2023-08-13 |
Not clear |
| Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R Hutso. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. vol 284. 2020-09-11. PMID:31931272. |
the experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. |
2020-09-11 |
2023-08-13 |
Not clear |
| Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R Hutso. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. vol 284. 2020-09-11. PMID:31931272. |
the current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. |
2020-09-11 |
2023-08-13 |
Not clear |
| Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R Hutso. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. vol 284. 2020-09-11. PMID:31931272. |
results tentatively support future research on psilocybin for the treatment of anxiety and depression. |
2020-09-11 |
2023-08-13 |
Not clear |
| Janis Fricke, Alexander Sherwood, Robert Kargbo, Andrew Orry, Felix Blei, Andreas Naschberger, Bernhard Rupp, Dirk Hoffmeiste. Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin. Chembiochem : a European journal of chemical biology. vol 20. issue 22. 2020-08-21. PMID:31150155. |
the pharmaceutical interest in psilocybin as a treatment option against depression and anxiety is currently being investigated in advanced clinical trials. |
2020-08-21 |
2023-08-13 |
Not clear |
| Janis Fricke, Robert Kargbo, Lars Regestein, Claudius Lenz, Gundela Peschel, Miriam A Rosenbaum, Alexander Sherwood, Dirk Hoffmeiste. Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin. Chemistry (Weinheim an der Bergstrasse, Germany). vol 26. issue 37. 2020-07-30. PMID:32101345. |
psilocybin, the principal indole alkaloid of psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatment-resistant depression and major depressive disorder. |
2020-07-30 |
2023-08-13 |
Not clear |
| Richard E Doblin, Merete Christiansen, Lisa Jerome, Brad Burg. The Past and Future of Psychedelic Science: An Introduction to This Issue. Journal of psychoactive drugs. vol 51. issue 2. 2020-05-22. PMID:31132970. |
this research includes clinical trials with mdma-assisted therapy for the treatment of ptsd, alcoholism, and social anxiety, and psilocybin clinical studies for depression and addiction, as well as the ability of psychedelics to catalyze spiritual or mystical experiences and inspire creativity, and into the neuroscientific understanding the effects of psychedelic substances on our nervous system. |
2020-05-22 |
2023-08-13 |
Not clear |
| Rémi Corne, Raymond Mongea. [Neurotrophic mechanisms of psychedelic therapy]. Biologie aujourd'hui. vol 213. issue 3-4. 2020-05-18. PMID:31829932. |
serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (lsd) are gaining attention as potential treatments for depression and addiction, similarly to 3,4-methylenedioxymethamphetamine (mdma) for post-traumatic stress disorder (ptsd), and ibogaine for addiction. |
2020-05-18 |
2023-08-13 |
Not clear |
| David Nut. Psychedelic drugs-a new era in
psychiatry?
. Dialogues in clinical neuroscience. vol 21. issue 2. 2020-04-03. PMID:31636488. |
these findings have led to the european medicines agency approving psilocybin for a phase 3 study in treatment-resistant depression and the food and drug administration for ptsd with mdma. |
2020-04-03 |
2023-08-13 |
Not clear |
| Oskar Jefsen, Kristoffer Højgaard, Sofie Laage Christiansen, Betina Elfving, David John Nutt, Gregers Wegener, Heidi Kaastrup Mülle. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta neuropsychiatrica. vol 31. issue 4. 2020-01-09. PMID:31106729. |
psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-resistant depression and other psychiatric illnesses. |
2020-01-09 |
2023-08-13 |
rat |